Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal
Publishing timestamp: 2025-05-01 10:59:47
Summary
Eli Lilly reported strong first-quarter earnings and revenue, driven by sales of weight loss drug Zepbound and diabetes treatment Mounjaro. However, the company lowered its full-year profit outlook due to charges related to a recent cancer treatment deal. CEO Dave Ricks discussed the impact of tariffs and tax rates on the pharmaceutical industry. Shares of Eli Lilly closed more than 11% higher after the earnings report.
Sentiment: MIXED
Keywords: biotech and pharmaceuticals, health care industry, united states, cvs health corp, business, lilly drn, biotechnology, donald trump, donald j. trump, pharmaceuticals, business news, earnings, breaking news: business, novo nordisk a/s,
Source: https://www.cnbc.com/2025/05/01/eli-lilly-lly-earnings-q1-2025.html